Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

150 7 Immunosuppresive Factors in Cancer
M. L. Kapsenberg. 1993. Prostaglandin
E2 differentially modulates cytokine secretion
profiles of human T helper lymphocytes.
J. Immunol. 150: 5321.
235 Demeure, C. E., L. P. Yang, C. Desjardins,
P. Raynauld and G. Delespesse.
1997. Prostaglandin E 2 primes naive T
cells for the production of anti-inflammatory
cytokines. Eur. J. Immunol. 27:
3526.
236 Sunder-Plassmann, R., H. Breiteneder,
K. Zimmermann, D. Strunk,
O. Majdic,W. Knapp and W. Holter.
1996. Single human T cells stimulated
in the absence of feeder cells transcribe
interleukin-2 and undergo long-term
clonal growth in response to defined
monoclonal antibodies and cytokine stimulation.
Blood 87: 5179.
237 Mesri, M., J. Liversidge and J. V. Forrester.
1996. Prostaglandin E 2 and
monoclonal antibody to lymphocyte
function-associated antigen-1 differentially
inhibit migration of T lymphocytes
across microvascular retinal endothelial
cells in rat. Immunology 88:471.
238 Elliott, L. H. and A. K. Levay. 1997.
Costimulation with dexamethasone and
prostaglandin E 2: a novel paradigm for
the induction of T-cell anergy. Cell Immunol.
180: 124.
239 Hale, A. H., D. L. Evans and L. W. Daniel.
1982. Effect of prostaglandins on
elicitation of anti-viral-cytolytic activity.
Immunol. Lett. 4: 171.
240 Wolf, M. and W. Droege. 1982. Inhibition
of cytotoxic responses by prostaglandin
E2 in the presence of interleukin
2. Cell Immunol. 72: 286.
241 Walker, T. M., A. D. Yurochko,
C. J. Burger and K. D. Elgert. 1992.
Cytokines and suppressor macrophages
cause tumor-bearing host CD8 + T cells
to suppress recognition of allogeneic
and syngeneic MHC class II molecules.
J. Leuk. Biol. 52: 661.
242 Specht, C., S. Bexten, E. Kolsch and
H. G. Pauels. 2001. Prostaglandins,
but not tumor-derived IL-10, shut down
concomitant tumor-specific CTL responses
during murine plasmacytoma
progression. Int. J. Cancer 91: 705.
243 Zielinski, C. C., C. Gisinger, C. Binder,
J. W. Mannhalter and M. M. Eibl.
1984. Regulation of NK cell activity by
prostaglandin E2: the role of T cells. Cell
Immunol. 87: 65.
244 Lala, P. K., R. S. Parhar and P. Singh.
1986. Indomethacin therapy abrogates
the prostaglandin-mediated suppression
of natural killer activity in tumorbearing
mice and prevents tumor metastasis.
Cell Immunol. 99: 108.
245 Scodras, J. M., R. S. Parhar, T. G. Kennedy
and P. K. Lala. 1990. Prostaglandin-mediated
inactivation of natural
killer cells in the murine decidua. Cell
Immunol. 127: 352.
246 Lauzon,W. and I. Lemaire. 1994. Alveolar
macrophage inhibition of lungassociated
NK activity: involvement of
prostaglandins and transforming
growth factor-b 1. Exp. Lung Res. 20:
331.
247 Baxevanis, C. N., G. J. Reclos,
A. D. Gritzapis, G. V. Dedousis,
I. Missitzis and M. Papamichail.
1993. Elevated prostaglandin E2 production
by monocytes is responsible for the
depressed levels of natural killer and
lymphokine-activated killer cell function
in patients with breast cancer. Cancer
72: 491.
248 Li,W. 1992. [Inhibition of growth and
metastasis of Lewis lung carcinoma in
C57BL mice immunized with PGE2±
bovine thyroglobulin conjugate]. Zhonghua
Zhong Liu Za Zhi 13: 427.
249 Young, M. R. and M. Dizer. 1983. Enhancement
of immune function and tumor
growth inhibition by antibodies
against prostaglandin E2. Immunol.
Commun. 12: 11.
250 Young, M. R. and S. Knies. 1984. Prostaglandin
E production by Lewis lung
carcinoma: mechanism for tumor establishment
in vivo. J. Natl Cancer Inst.
72: 919.
251 Maca, R. D. 1988. Inhibition of the
growth of Lewis lung carcinoma by indomethacin
in conventional, nude and
beige mice. J. Biol. Resp. Modif. 7: 568.
252 Specht, C., S. Bexten, E. Kolsch and
H. G. Pauels. 2001. Prostaglandins,
but not tumor-derived IL-10, shut down
concomitant tumor-specific CTL responses
during murine plasmacytoma
progression. Int. J. Cancer 91: 705.